Brett Andrew King MD PhD

Dermatology•Fairfield, CT

Physician

Join to View Full Profile

425 Post Road2nd FloorFairfield, CT 06824
Phone+1 203-292-9490
Fax+1 203-292-9487

Summary

I was the first dermatologist to show that a class of medicines called Janus kinase (JAK) inhibitors were effective for treatment of alopecia areata, vitiligo, atopic dermatitis (eczema), granuloma annulare, sarcoidosis, lichen planus, and other disorders. I have advanced the use of oral minoxidil for treatment of male and female pattern hair loss (also called androgenetic alopecia) and other hair loss disorders.

After completing medical training at Yale School of Medicine, I spent 14 years on the full-time faculty at the Yale School of Medicine before recently transitioning to private practice in order to focus on patient care, clinical research and medical education. I have been an investigator in numerous clinical trials, including those leading to approval of Olumiant, Litfulo and Leqselvi for treatment of alopecia areata. I lecture nationally and internationally and publish extensively.

Education & Training

Yale-New Haven Medical CenterResidency, Dermatology, 2006 - 2009
Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 2005 - 2006
Yale School of MedicineClass of 2005
Stanford UniversityPh.D., Chemistry, 2000
University of California, Santa CruzB.A., Chemistry, 1992

Certifications & Licensure

CT State Medical License 2009 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Patient Care Hero American Academy of Dermatology, 2022
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Mentorship Award Women’s Dermatologic Society, 2008
Alpha Omega Alpha Society 2005
Fellow (FAAD) American Academy of Dermatology
Join now to see all

Clinical Trials

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Start of enrollment: 2010 Oct 01
Terminated
Phase 1, Phase 2
Tofacitnib for the Treatment of Alopecia Areata and Variants Start of enrollment: 2014 Jul 01
Completed
Phase 2
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants Start of enrollment: 2016 Sep 01
Completed
Phase 2
Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling Start of enrollment: 2021 Apr 09
Completed
Not Applicable
Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling Start of enrollment: 2021 Apr 09
Completed
Not Applicable
Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling Start of enrollment: 2021 Apr 09
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment.
Brett King, Arash Mostaghimi, Yutaka Shimomura, Bianca Maria Piraccini, Ulrike Blume-Peytavi
American Journal of Clinical Dermatology. 2025-04-11
Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Arash Mostaghimi, Brittany Craiglow, Brett King, Jerry Shapiro, Justin Ko
The British Journal of Dermatology. 2025-04-03
Correction: Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, Brett King, Emma Guttman-Yassky
Archives of Dermatological Research. 2025-03-12

Journal Articles

Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management
Brett A King, Ian W Tattersall, Paul A Gaudio, JAMA
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis
Craiglow BG, King BA, J Invest Dermatol, 1/1/2014
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Levy LL, Urban J, King BA, J Am Acad Dermatol, 1/1/2015
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy
Craiglow BG, King BA, JAMA Dermatol, 1/1/2015
Psychophysical measurements of itch and nociceptive sensations in an experimental model of allergic contact dermatitis
Pall PS, Hurwitz OE, King BA, LaMotte RH, J Pain, 1/1/2015
Purpuric Lesions on Acral Sites Type I cryoglobulinemia associated with multiple myeloma
Fraser Gibson J, Leventhal JS, King B, JAMA Dermatol, 1/1/2015
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination t...
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Mavera..., J Am Acad Dermatol, 1/1/2015
Divalproex sodium: A potential therapy for scleroderma digital ulcers
Urban JR, King B, J Am Acad Dermatol, 1/1/2015
When erythema ab igne warrants an evaluation for internal malignancy
Bunick CG, Ibrahim O, King BA, Int J Dermatol, 1/1/2014
Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines
Patel F, Wilken R, Burrall B, Martinez S, Wells V, King B, Maverakis E, Dermatol Online J, 1/1/2014
Capillary malformation--arteriovenous malformation syndrome: review of the literature, proposed diagnostic criteria, and recommendations for management
Orme CM, Boyden LM, Choate KA, Antaya RJ, King BA, Pediatr Dermatol, 1/1/2013
Atypical hand-foot-and-mouth disease associated with coxsackievirus A6 infection
Lott JP, Liu K, Landry ML, Nix WA, Oberste MS, Bolognia J, King B, J Am Acad Dermatol, 1/1/2013
An unusual clinical and histologic presentation of disseminated cutaneous histoplasmosis
Srivastava B, King B, Galan A, J Am Acad Dermatol, 1/1/2011
Palifermin-associated papular eruption
King B, Knopp E, Galan A, Nuovo G, Tigelaar R, McNiff J, Arch Dermatol, 1/1/2009
Join now to see all

Lectures

Alopecia: Work-up and Treatment
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
Controversies in Dermatology: Stevens-Johnson Syndrome/TEN
Miami Beach, FL - 1/1/2010
TEN 2011
New York, NY - 1/1/2010
Excited State Dynamics in Green-, Blue-, and Red-fluorescent Proteins: Multiple States and Proton Transfer
New Brunswick, NY - 1/1/1997
Join now to see all